RARA CRAFT DATABASE for FDA Medical Devices

FDA medical device news and insights

News articles that explain new FDA clearances and approvals, guidance, AI devices and premarket pathways in plain terms — for product development and regulatory teams.

The 3 newest articles are free to read in full. Members can read every article.

日本語の記事
  1. Monthly FDA ApprovalsMembersDoes Every Breakpoint Revision or New Connection Need a 510(k)? The Conditions September 2026's PCCPs Set in AdvanceA PCCP is not only for retraining an AI model. Among the eighteen FDA decisions with a PCCP in September 2026, several plan to re-evaluate antimicrobial breakpoints, add operating systems and data connections to insulin-dosing apps, add compatible insulins to an insulin pump, move a catheter's manufacturing site or extend a test to more laboratories. We trace them back through the same companies' earlier filings and FDA's review documents. What the 510(k) Summaries leave out, FDA's Decision Summaries and the approval statements on PMA records often supply.
  2. Monthly FDA ApprovalsMembersWhat Is a Retrained AI Compared With Before It Goes Live? Seven PCCPs from September 2026, One Retraining DailySeven devices cleared with a PCCP in September 2026 could be confirmed as AI/ML. We read each 510(k) Summary against what FDA's AI PCCP guidance asks for, a description of modifications, a modification protocol, an impact assessment and labeling. What a retrained model is compared with, how much of the acceptance criteria is public, and how an update is adopted vary from one Summary to the next. Set beside other plans from the same companies, the differences in public documents are kept apart from differences in the plans themselves.
  3. Monthly FDA ApprovalsMembersFrom a Manufacturing Site to Test Breakpoints: What September 2026's Eighteen PCCPs Plan to ChangeEighteen FDA decisions in September 2026 came with a Predetermined Change Control Plan. We checked each one in whichever of the 510(k) Summary, the clearance letter, FDA's Decision Summary and the approval statement on FDA's PMA record are public, and kept three things apart, whether the device uses AI, what the plan covers, and how far the public documents let us confirm it. Besides retraining an AI model, the plans cover re-evaluating antimicrobial breakpoints, adding operating systems, data connections and compatible insulins, moving a manufacturing site and extending use to more laboratories.
  4. Monthly FDA ApprovalsMembersFDA Guidance and Notices, September 2026: Draft Guidance on Robotically-Assisted Surgical Devices and a PMA Electronic Submission TemplateFDA's device-related guidance, rules and notices from September 2026, with a short note on each: draft guidance on robotically-assisted surgical devices and a PMA electronic submission template, final 510(k) guidance for two dental device types, and new work on rare disease devices.
  5. Monthly FDA ApprovalsMembersFDA Guidance and Notices, August 2026: Revised Human Factors Guidance and a Discussion Paper on Generative AI DevicesFDA's device-related guidance, rules and notices from August 2026, each with a short note. Highlights include the revised human factors and usability engineering guidance, a discussion paper on generative AI-enabled devices and a proposed list of accessories suitable for class I.
  6. Monthly FDA ApprovalsFDA Device Decisions, August 2026: A Blood-Drawing Robot, a Glucose-Ketone CGM and Five New De Novo ClassificationsWhat FDA cleared, granted and approved in August 2026, from RA Craft Database's tally and FDA's public records. The five De Novo grants, including an autonomous phlebotomy robot and a combined glucose-ketone sensor, each created a new classification; we read their indications and special controls, then the month's three original PMAs.
  7. Monthly FDA ApprovalsMembersFDA Guidance and Notices, July 2026: MDUFA VI Proposals and FY2027 Device User FeesFDA's device-related guidance, rules and notices from July 2026, briefly explained. The month brought the proposed MDUFA VI package for comment, fiscal year 2027 user fees and final guidance on 510(k) submissions for hemodialysis blood tubing sets.
  8. Monthly FDA ApprovalsFDA Device Decisions, July 2026: A Surgical Robot, Five De Novo Grants and Four Original PMAsWhat FDA cleared, granted and approved in July 2026, tallied from records held in RA Craft Database. Counts by pathway against June and July 2025, the busiest product codes, all five De Novo grants and four original PMAs, and three devices worth a closer read.
  9. Monthly FDA ApprovalsMembersFDA Guidance and Notices, June 2026: Final Policy on Exempting Unclassified Devices From 510(k), and a Wave of Classification RulesFDA's device-related guidance, rules and notices from June 2026, with a short note on each. FDA updated its final policy on exempting certain unclassified devices from 510(k), and a long run of classification rules appeared.
  10. Monthly FDA ApprovalsFDA Device Decisions, June 2026: A Blood Test for Esophageal Varices, Six Original PMAs and One De Novo GrantWhat FDA cleared, granted and approved in June 2026, tallied from records held in RA Craft Database. Counts by pathway against May and June 2025, the busiest product codes, the month's De Novo grant and six original PMAs, and three devices worth a closer read.
  11. Monthly FDA ApprovalsMembersFDA Guidance and Notices, May 2026: Final Guidance on Human Factors Information and Patient-Matched Orthopedic GuidesA list of FDA's device-related guidance, rules and notices from May 2026, with a short note on each. Final guidance on human factors information in marketing submissions and on patient-matched guides for orthopedic implants came out this month.
  12. Monthly FDA ApprovalsFDA Device Decisions, May 2026: A Home Neurostimulator for PTSD, Four De Novo Grants and Five Original PMAsWhat FDA cleared, granted and approved in May 2026, tallied from records held in RA Craft Database. Counts by pathway against April and May 2025, the busiest product codes, all four De Novo grants and five original PMAs, and three devices worth a closer read.
  13. Monthly FDA ApprovalsMembersFDA Guidance and Notices, April 2026: The FDA-CMS RAPID Pathway and Device Classification RulesFDA's device-related announcements, guidance and rules from April 2026, with brief notes. The list covers the FDA-CMS RAPID pathway, the READI-Home innovation challenge, a draft on NIOSH-approved respirators and a set of device classification rules.
  14. Monthly FDA ApprovalsFDA Device Decisions, April 2026: MRI Software for Parkinsonian Syndromes, Three De Novo Grants and One Original PMAWhat FDA cleared, granted and approved in April 2026, tallied from records held in RA Craft Database. Counts by pathway against March and April 2025, the busiest product codes, all three De Novo grants and the month's original PMA, and three devices worth a closer read.
  15. Monthly FDA ApprovalsMembersFDA Guidance and Notices, March 2026: Final Guidance on Weight-Loss Devices and Patient Preference InformationFDA's device-related guidance, rules and safety communications from March 2026, briefly explained. Final guidance on weight-loss devices, pyrogen and endotoxins testing, and patient preference information is listed alongside a batch of withdrawn older guidance.
  16. Monthly FDA ApprovalsFDA Device Decisions, March 2026: An Anti-Choking Device, a Transcatheter Valve for Aortic Regurgitation and MoreWhat FDA cleared, granted and approved in March 2026, tallied from records held in RA Craft Database. Counts by pathway against February and March 2025, the busiest product codes, both De Novo grants and the month's original PMAs, and three devices worth a closer read.
  17. Monthly FDA ApprovalsMembersFDA Guidance and Notices, February 2026: A QMSR Inspection Program and Revised Cybersecurity GuidanceFDA's device-related guidance, rules and notices from February 2026, the month a QMSR-based inspection program began. Revised cybersecurity and software assurance guidance and proposed 510(k) exemptions for Class II devices are among the items, each with a short note.
  18. Monthly FDA ApprovalsFDA Device Decisions, February 2026: An AI That Predicts Delivery Dates, Two De Novo Grants and Five Original PMAsWhat FDA cleared, granted and approved in February 2026, tallied from records held in RA Craft Database. Counts by pathway against January and February 2025, the busiest product codes, both De Novo grants and all five original PMAs, and three devices worth a closer read.
  19. Monthly FDA ApprovalsMembersFDA Guidance and Notices, January 2026: Final Guidance on Clinical Decision Support Software and General WellnessFDA's device-related guidance and notices from January 2026, with a line or two on each. The month brought final guidance on clinical decision support software and on low-risk general wellness products, and a draft on cuffless blood pressure devices.
  20. Monthly FDA ApprovalsFDA Device Decisions, January 2026: A Liquid Embolic for Chronic Subdural Hematoma, Two De Novo Grants and Two Original PMAsWhat FDA cleared, granted and approved in January 2026, tallied from records held in RA Craft Database. Counts by pathway against December and January 2025, the busiest product codes, both De Novo grants and both original PMAs, and three devices worth a closer read.
  21. Monthly FDA ApprovalsFDA Guidance and Notices, December 2025: Final Guidance on Real-World Evidence for Devices and QMSR Technical AmendmentsA list of FDA's device-related guidance, rules and notices from December 2025, each with a brief note. Highlights are final guidance on real-world evidence for devices and on eCopy, QMSR technical amendments, and the TEMPO pilot for digital health devices.
  22. Monthly FDA ApprovalsFDA Device Decisions, December 2025: Transcatheter Mitral Valve Replacement, Home Neurostimulation for Depression and Ten Original PMAsWhat FDA cleared, granted and approved in December 2025, tallied from records held in RA Craft Database. Counts by pathway against November and December 2024, the busiest product codes, both De Novo grants and all ten original PMAs, and three devices worth a closer read.
  23. Monthly FDA ApprovalsFDA Guidance and Notices, November 2025: Final Guidance on Pre-RFDs and Draft ICH Q3E on Extractables and LeachablesFDA's device-related guidance, rules, notices and safety communications from November 2025, with brief notes. FDA finalized guidance on preparing a Pre-Request for Designation (Pre-RFD) and released the draft ICH Q3E guideline on extractables and leachables.
  24. Monthly FDA ApprovalsFDA Device Decisions, November 2025: Focused Ultrasound for Facet Joint Pain, Two De Novo Grants and Two Original PMAsWhat FDA cleared, granted and approved in November 2025, tallied from records held in RA Craft Database. Counts by pathway against October and November 2024, the busiest product codes, both De Novo grants and both original PMAs, and three devices worth a closer read.
  25. Monthly FDA ApprovalsFDA Guidance and Notices, October 2025: Draft Guidance on QMS Information in Premarket Reviews and a Warning on RF MicroneedlingFDA's device-related guidance and safety communications from October 2025, each with a brief note. FDA issued drafts on quality management system information for certain premarket reviews and on menstrual products, and warned about radiofrequency (RF) microneedling.
  26. Monthly FDA ApprovalsFDA Device Decisions, October 2025: Cryoablation for Low-Risk Breast Cancer, Home Fetal Ultrasound and Four De Novo GrantsWhat FDA cleared, granted and approved in October 2025, tallied from records held in RA Craft Database. Counts by pathway against September and October 2024, the busiest product codes, all four De Novo grants and the original PMA, and three devices worth a closer read.
  27. Monthly FDA ApprovalsFDA Guidance and Notices, September 2025: Final Computer Software Assurance Guidance and the LDT Rule VacaturFDA's device-related guidance, rules, advisory committee notices and safety communications from September 2025, each briefly explained. The main items are final guidance on computer software assurance for production and quality system software and a rule implementing the court's vacatur of the laboratory developed test (LDT) rule.
  28. Monthly FDA ApprovalsFDA Device Decisions, September 2025: Spectacle Lenses to Slow Myopia in Children, Three De Novo Grants and Four Original PMAsWhat FDA cleared, granted and approved in September 2025, tallied from records held in RA Craft Database. Counts by pathway against August and September 2024, the busiest product codes, all three De Novo grants and four original PMAs, and three devices worth a closer read.
  29. Monthly FDA ApprovalsFDA Guidance and Notices, August 2025: Revised PCCP Guidance for AI-Enabled Devices and a Batch of Classification RulesFDA's device-related guidance, rules and letters to health care providers from August 2025, with a short note on each. FDA revised its final guidance on Predetermined Change Control Plans (PCCPs) for AI-enabled devices, issued final guidance on animal studies for dental bone grafting materials, and published a batch of classification rules.
  30. Monthly FDA ApprovalsFDA Device Decisions, August 2025: Pulsed Field Ablation, Bilateral Hypoglossal Nerve Stimulation and Six Original PMAsWhat FDA cleared, granted and approved in August 2025, tallied from records held in RA Craft Database. Counts by pathway against July and August 2024, the busiest product codes, the De Novo grant and all six original PMAs, and three devices worth a closer read.
  31. Monthly FDA ApprovalsFDA Guidance and Notices, July 2025: FY2026 Device User Fees and Final Guidance on Small Business QualificationFDA's device-related guidance, notices and safety updates from July 2025, with a short note on each. The month brought the fiscal year 2026 device user fee rates and final guidance on qualifying as a small business.
  32. Monthly FDA ApprovalsFDA Device Decisions, July 2025: Vagus Nerve Stimulation for Rheumatoid Arthritis, Four Original PMAs and One De Novo GrantWhat FDA cleared, granted and approved in July 2025, tallied from records held in RA Craft Database. Counts by pathway against June and July 2024, the busiest product codes, the De Novo grant and all four original PMAs, and three devices worth a closer read.
  33. Monthly FDA ApprovalsFDA Guidance and Notices, June 2025: Cybersecurity Final Guidance and Draft Guidance on 510(k) Clearance TransfersFDA's device-related guidance, rules, notices and safety communications from June 2025, briefly annotated. Among them are final cybersecurity guidance, a draft on 510(k) clearance transfers and a call for comments on MDUFA reauthorization.
  34. Monthly FDA ApprovalsFDA Device Decisions, June 2025: A Bone Graft That Beat Autograft in Lumbar Fusion, Sutureless Nerve Repair and Three De Novo GrantsWhat FDA cleared, granted and approved in June 2025, tallied from records held in RA Craft Database. Counts by pathway against May and June 2024, the busiest product codes, all three De Novo grants and all three original PMAs, and three devices worth a closer read.
  35. Monthly FDA ApprovalsFDA Guidance and Notices, May 2025: Q-Submission Program Final Guidance and a Draft Electronic TemplateFDA's device-related guidance, rules and announcements from May 2025, with brief notes. The month brought final guidance on the Q-Submission Program and a draft electronic template for it, an expansion of unannounced foreign inspections and a batch of device classification rules.
  36. Monthly FDA ApprovalsFDA Device Decisions, May 2025: A Transcatheter Mitral Valve for Severe Annular Calcification, Five-Year Breast Cancer Risk Software and Four De Novo GrantsWhat FDA cleared, granted and approved in May 2025, tallied from records held in RA Craft Database. Counts by pathway against April and May 2024, the busiest product codes, all four De Novo grants and all three original PMAs, and three devices worth a closer read.
  37. Monthly FDA ApprovalsFDA Guidance and Notices, April 2025: False Positive Blood Lead Results and the STIC Annual CompilationThe two device-related documents FDA issued in April 2025, with notes: a safety communication on false positive blood lead results, and the Federal Register compilation of 2024 updates to the Susceptibility Test Interpretive Criteria (STIC).
  38. Monthly FDA ApprovalsFDA Device Decisions, April 2025: Leadless Left-Ventricular Pacing, Behavioral Therapy Software for Migraine, Four De Novo Grants and Three Original PMAsWhat FDA cleared, granted and approved in April 2025, tallied from records held in RA Craft Database. Counts by pathway against March and April 2024, the busiest product codes, all four De Novo grants and all three original PMAs, and three devices worth a closer read.
  39. Monthly FDA ApprovalsFDA Guidance and Notices, March 2025: Sex-Specific Data in Device Clinical Studies and a Recognized Standards UpdateFDA's device-related guidance, notices and other documents from March 2025, each with a short note. The main ones are final guidance on sex-specific data in device clinical studies and Recognition List 063; there was also a letter on hemodialysis bloodline shortages.
  40. Monthly FDA ApprovalsFDA Device Decisions, March 2025: An Over-the-Counter PCR Test for Sexually Transmitted Infections, an Endoscope Channel Cleaner and No Original PMAsWhat FDA cleared, granted and approved in March 2025, tallied from records held in RA Craft Database. Counts by pathway against February and March 2024, the busiest product codes, and both De Novo grants. There were no original PMA approvals in March.
  41. Monthly FDA ApprovalsFDA Guidance and Notices, February 2025: IRB Written Procedures and Smartphone Alerts for Diabetes DevicesThe two device-related documents FDA issued in February 2025, with a short note on each: a revised final guidance on IRB written procedures and a safety communication on smartphone alert settings for diabetes devices.
  42. Monthly FDA ApprovalsFDA Device Decisions, February 2025: A Hyaluronic Acid Filler, a Spine Sealant and No De Novo GrantsWhat FDA cleared, granted and approved in February 2025, tallied from records held in RA Craft Database. Counts by pathway against January and February 2024, the busiest product codes, and both original PMAs. There were no De Novo grants in February.
  43. Monthly FDA ApprovalsFDA Guidance and Notices, January 2025: Draft Guidance on AI-Enabled Device Lifecycle Management and Pulse OximetersFDA's device-related guidance, rules and safety communications from January 2025, each with a short note. They include draft guidance on AI-enabled device software lifecycle management and on pulse oximeters, and final guidance on PMA and HDE modular review.
  44. Monthly FDA ApprovalsFDA Device Decisions, January 2025: Kidney Function Measured Through the Skin, a Muscle-Fatigue Device for Athletes and Two Original PMAsWhat FDA cleared, granted and approved in January 2025, tallied from records held in RA Craft Database. Counts by pathway against December 2024 and January 2024, the busiest product codes, the De Novo grant and both original PMAs, and three devices worth a closer read.